OKYO Reports Upcoming CEO Presentation at Eyecelerator May 1 2026, CSO to Present at ARVO May 5 2026, Urcosimod Phase 2 Success, Fast Track Designation, 18-Patient NCP Trial Shows Pain Reduction, Phase 2b/3 Study Planned 2026
OKYO Pharma Limited Ordinary Shares · Now $1.71
+11% in 3d after detection
Post-detection moves
1h
—
1d
+2.6%
3d
+11%
7d
+7.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS